Obigen Pharma Inc. (TPEX:7876)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
36.35
-0.15 (-0.41%)
At close: Jun 18, 2026
Market Cap3.89B
Revenue (ttm)n/a
Net Income-325.96M
EPS-3.07
Shares Out 106.92M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume67,003
Open35.85
Previous Close36.50
Day's Range35.50 - 36.35
52-Week Range33.75 - 69.00
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About Obigen Pharma

Obigen Pharma Inc. engages in research, manufacturing, and promotion of biotechnology and novel botulinum toxin. Preparations in Taiwan. Its lead product OBI-858, a 760 kDa novel toxin protein which fermented and purified from clostridium botulinum type A bacteria, which is in Phase II clinical trial. The company was founded in 2020 and is based in Zhubei, Taiwan. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2020
Employees 60
Stock Exchange Taipei Exchange
Ticker Symbol 7876
Full Company Profile

Financial Performance

Financial Statements